Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02683772 · ClinicalTrials.gov registry record · Phase 3
Astral VAPS AutoEPAP Clinical Trial
A Phase 3 study, sponsored by ResMed.
- Completed
- Registry status
- Phase 3
- Development phase
- 42
- Enrollment target
NCT02683772 is a Phase 3 study that has completed, run by ResMed. The registered enrollment target is 42 participants.
The verdict
NCT02683772, a Phase 3 study, has completed, sponsored by ResMed.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 42 participants
- Enrollment target
Study Summary
Patients with chronic respiratory failure such as those associated with Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS), Obstructive Sleep Apnea (OSA) or Neuromuscular Disease (NMD) are increasingly managed with domiciliary non-invasive positive pressure ventilation (NIPPV). The aim of this study is to now compare the Automatic Expiratory Positive Airway Pressure (AutoEPAP) algorithm with a fixed manual EPAP in iVAPS mode on an Astral mixed mode ventilator. It is proposed that the automatic settings of AutoEPAP will be as effective at managing respiratory failure and upper airway obstruction (UAO) as manual EPAP on the Astral device. Specifically demonstrating that the AutoEPAP function is as effective at treating UAO as manual EPAP.
Interventions
- DEVICE Astral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2016-04-15 |
| Est. Completion | 2017-07-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02683772
The ClinicalTrials.gov registry entry for NCT02683772 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ResMed, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Astral is the first listed.
NCT02683772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02683772 about?
NCT02683772 is a clinical study titled "Astral VAPS AutoEPAP Clinical Trial". Patients with chronic respiratory failure such as those associated with Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS), Obstructive Sleep Apnea (OSA) or Neuromuscular Disease (NMD) are increasingly managed with domiciliary non-invasive positive pressure ventilat...
What is the current status of trial NCT02683772?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 42 participants. The study started on 2016-04-15. Estimated completion is 2017-07-06.
What interventions are being tested in trial NCT02683772?
The interventions under investigation include: Astral (DEVICE).
Who is sponsoring clinical trial NCT02683772?
This trial is sponsored by ResMed, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.